NCT00066443 2026-03-27
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
Clinical Trials
173 trialsNCT05296317 2026-02-19
EMEG-ECDD
Centre Georges Francois Leclerc
Phase NA Completed
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01850888 2025-12-18
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT02369458 2025-11-18
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Washington University School of Medicine
Phase 2 Completed
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04383743 2025-09-18
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Phase 2 Completed
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00911183 2025-08-29
FRAIL-06
Institut Bergonié
Phase 2 Completed
NCT00049595 2025-08-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00812669 2025-07-08
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Cancer Trials Ireland
Phase 2 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT04781959 2025-03-21
A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy
Ottawa Hospital Research Institute
Phase 4 Completed
NCT04023669 2025-02-07
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00670358 2025-01-10
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT02073097 2024-05-29
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT04345900 2024-05-16
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT00678327 2024-05-08
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
Phase 3 Completed
NCT00837265 2024-04-03
NEUGR-002
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2/3 Completed
NCT05283616 2024-03-19
Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Completed
NCT06309732 2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2 Completed
NCT00304070 2024-02-28
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Children's Oncology Group
Phase 3 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT00004192 2023-12-27
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT02834403 2023-12-15
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT02728531 2023-11-01
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 1 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT00146562 2023-08-02
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT04687098 2023-06-27
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase 2 Completed
NCT01256398 2023-04-04
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01126190 2023-03-28
NEUGR-003
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT05338047 2023-02-28
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Completed
NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00346125 2022-12-15
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01879085 2022-09-21
GemTax
University of Pittsburgh
Phase 1/2 Completed
NCT02698891 2022-05-06
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00887536 2022-04-20
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01724866 2022-04-15
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT00063999 2021-10-19
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
GOG Foundation
Phase 3 Completed
NCT01847001 2021-09-10
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Columbia University
Phase 2 Completed